Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Meta-analysis
100%
Type 2 Diabetes Mellitus (T2DM)
89%
Odds Ratio
51%
Time-dependent Risk
44%
One-stage Network
44%
Living Systematic Review
44%
Depression Recurrence
44%
Modeling Effect
44%
Treatment Duration
44%
Treatment Intensity
44%
Missing Outcome Data
44%
Component Effects
44%
Antidiabetic Drug
44%
Patient-reported Outcomes
44%
Fracture Risk
44%
Time-varying Cost
44%
Missing Data
44%
Thiazolidinediones
37%
Glucagon-like
37%
Receptor Agonist
37%
1 Receptor
37%
Randomized Controlled Trial
32%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
29%
Tirzepatide
29%
Credible Interval
29%
Finerenone
22%
Hazard Ratio
22%
Acceleration Factor
19%
Grading of Recommendations
18%
Assessment Development
18%
Assessment Evaluation
18%
Treatment Effect
16%
MEDLINE
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Embase
14%
Sulfonylurea
14%
Kidney
14%
Risk Stratification
14%
Nonrandomized Studies
14%
Rapid Recommendations
14%
Reduced Time
12%
Low Intensity
12%
Population Heterogeneity
12%
Recurrence Rate
12%
Evaluation Approach
10%
Assessment Approach
10%
Development Approach
10%
Patient-Reported Outcomes Measurement Information System (PROMIS)
10%
Parameter Decomposition
8%
Chronic Kidney Disease
7%
Medicine and Dentistry
Systematic Review
89%
Maturity Onset Diabetes of the Young
89%
Sodium-Glucose Cotransporter 2 Inhibitors
67%
Chronic Kidney Disease
63%
Cardiovascular System
59%
Sodium Glucose Cotransporter 2 Inhibitor
44%
Meta-Analysis
44%
Chronic Disease
44%
Proteomics
44%
Metabolic Dysfunction-Associated Steatotic Liver Disease
44%
Network Meta-Analysis
44%
Odds Ratio
44%
Glucagon-Like Peptide-1 Agonist
37%
Tirzepatide
29%
Congestive Heart Failure
27%
Diabetes
24%
Steatosis
22%
Randomized Controlled Trial
22%
Finerenone
22%
Diseases
16%
Liver Fibrosis
16%
Renal Failure
14%
Placebo
12%
Genital Tract Infection
12%
Ketoacidosis
12%
Chronic Respiratory Tract Disease
11%
Respiration Depression
11%
Mediator
11%
Cardiovascular Disease
11%
High Risk Population
9%
Treatment Effect
9%
Severe Hypoglycemia
7%
Fragility Fracture
7%
Dipeptidyl Peptidase-4 Inhibitor
7%
Thiazolidinedione
7%
Insulin
7%
Body Weight
7%
Neuropathy
7%
Visual Impairment
7%
Amputation
7%
Sulfonylurea
7%
Hyperkalemia
7%
Patient with Type 2 Diabetes
7%
Attributable Risk
5%
UK Biobank
5%
Cumulative Incidence
5%
Serum Total Protein
5%
Proportional Hazards Model
5%
Proteome
5%
Hazard Ratio
5%
